Abstract
Nowadays, the position of sorafenib in thetreatmentofadvancedhepatocellularcarcinoma(HCC)isfrequentlychallengedbyothermoleculartargetedagents.However,regardlessofwhether they are considered as first-line or second-line treatmentoptions,allcompletedphaseIIIrandomizedcontrolledtrials(RCTs)reportnegativeresults.Similarly,twophaseIIIRCTs(ComparisonofBrivanibandBestSupportiveCaretoPlacebo BestSupportiveCarein Subjects With Advanced Hepatocellular Cancer Who Have Failedor Are Intolerant to Sorafenib Treatment [BRISK-PS] and A Ran-domized, Double-Blind, Multi-Center Phase III Study of BrivanibVersusSorafenibAsFirst-LineTreatmentinPatientsWithAdvancedHepatocellularCarcinoma[BRISK-FL])thatwererecentlypublishedin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
